You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CPD

The Potential of Antibody-Drug Conjugates in Non-Small Cell Lung Cancer: From Mechanism to Action

  • Authors: Hossein Borghaei, DO, MS; Antonio Passaro, MD, PhD; Ticiana Leal, MD 
  • CPD Released: 8/26/2022
  • Valid for credit through: 8/26/2023
Start Activity

  • Credits Available

    Non-US Physicians - maximum of 0.75 CPD

    You Are Eligible For

    • Letter of Completion

Target Audience and Goal Statement

This activity is intended for an international audience of hematology/oncology specialists, pathologists, pulmonologists, and other members of the oncology care team.

The goal of this activity is that learners will be better able to understand the latest developments of antibody-drug conjugates (ADCs) in the treatment of non-small cell lung cancer (NSCLC).

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Mechanism of action of ADCs
    • Latest clinical trials investigating ADCs in NSCLC
  • Have greater competence related to
    • Diagnosing molecular alterations that are amenable to treatment with ADCs
  • Demonstrate greater confidence in their
    • Understanding of the implications of the latest clinical evidence for ADCs in NSCLC


Disclosures

WebMD Global requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships with ineligible companies.


CHAIR/MODERATOR

  • Hossein Borghaei, DO, MS

    Professor, Department of Hematology/Oncology
    Chief, Division of Thoracic Medical Oncology
    The Gloria and Edmund M. Dunn Chair in Thoracic Oncology
    Fox Chase Cancer Center
    Philadelphia, Pennsylvania, United States

    Disclosures

    Hossein Borghaei, DO, MS, has the following relevant financial relationships:
    Consultant or advisor for: Amgen; AstraZeneca; Axiom; BeiGene; BioNTech; Boehringer Ingelheim; Bristol Myers Squibb; Da Volterra; Daiichi Sankyo; EMD Serono; Genentech; Genmab; Guardant Health; iTeos Therapeutics; Janssen; Jazz Pharmaceuticals; Lilly; Merck; Mirati Pharmaceuticals; Natera; Novartis; Oncocyte; PharmaMar; Pfizer; Regeneron; Takeda
    Research funding from: Amgen; Bristol Myers Squibb; Lilly
    Stock options from: Inspirna (formerly Rgenix); Nucleai; Sonnet BioTherapeutics
    Other: Data and Safety Monitoring Board: Incyte; Novartis; Takeda

  • Antonio Passaro, MD, PhD

    Medical Oncologist
    Division of Thoracic Oncology
    IRCCS European Institute of Oncology
    Milan, Italy

    Disclosures

    Antonio Passaro, MD, PhD, has the following relevant financial relationships:
    Consultant or advisor for: AstraZeneca; Boehringer Ingelheim; Bristol Myers Squibb; Eli Lilly and Company; Genentech; Janssen; Merck Sharp & Dohme; Novartis; Pfizer; Roche; Takeda
    Speaker or member of speakers bureau for: AstraZeneca; Boehringer Ingelheim; Bristol Myers Squibb; Janssen; Takeda

  • Ticiana Leal, MD

    Associate Professor
    Department of Hematology and Oncology
    Director, Thoracic Medical Oncology
    Winship Cancer Institute
    Emory University
    Atlanta, Georgia, United States

    Disclosures

    The opinions expressed are those of Dr Leal and do not necessarily reflect the views of Emory University or Emory Healthcare. Dr Leal’s participation in this activity does not constitute or imply endorsement by Emory University or Emory Healthcare.

    Ticiana Leal, MD, has the following relevant financial relationships:
    Consultant or advisor for: Amgen; AstraZeneca; Bayer; Blueprint; Boehringer Ingelheim; Daiichi Sankyo; Eisai; EMD Serono; Genentech; Janssen; Jazz Pharmaceuticals; Lilly; Merck; Mirati; Novocure; Roche; Takeda

Editor

  • Megan Cannon, PhD

    Medical Education Director, WebMD Global, LLC

    Disclosures

    Megan Cannon, PhD, has no relevant financial relationships.

Compliance Reviewer

  • Yaisanet Oyola, MD, PhDc

    Associate Director, Accreditation and Compliance

    Disclosures

    Yaisanet Oyola, MD, PhDc, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.


Accreditation Statements

    For Physicians

  • The Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom (FPM) has reviewed and approved the content of this educational activity and allocated it 0.75 continuing professional development credits (CPD). 

    Contact WebMD Global

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information about your eligibility to claim credit, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent participating in the activity. To successfully earn credit, participants must complete the activity online during the credit eligibility period that is noted on the title page.

Follow these steps to claim a credit certificate for completing this activity:

  1. Read the information provided on the title page regarding the target audience, learning objectives, and author disclosures, read and study the activity content and then complete the post-test questions. If you earn a passing score on the post-test and we have determined based on your registration profile that you may be eligible to claim CPD credit for completing this activity, we will issue you a CPD credit certificate.
  2. Once your CPD credit certificate has been issued, you may view and print the certificate from your CME/CE Tracker. CPD credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of the Medscape Education homepage.

We encourage you to complete an Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of your Medscape homepage.

*The credit that you receive is based on your user profile.

CPD

The Potential of Antibody-Drug Conjugates in Non-Small Cell Lung Cancer: From Mechanism to Action

Authors: Hossein Borghaei, DO, MS; Antonio Passaro, MD, PhD; Ticiana Leal, MD Faculty and Disclosures

CPD Released: 8/26/2022

Valid for credit through: 8/26/2023

processing....

Educational Impact Challenge

The goal of this activity is that learners will be better able to understand the latest developments in antibody-drug conjugates (ADCs) in the treatment of non-small cell lung cancer (NSCLC).

Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.